Rituximab treatment in myasthenia gravis
Myasthenia gravis (MG) is a chronic autoimmune disease mediated by antibodies against post-synaptic proteins of the neuromuscular junction. Up to 10%–30% of patients are refractory to conventional treatments. For these patients, rituximab has been used off-label in the recent decades. Rituximab is a...
שמור ב:
| Principais autores: | , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Frontiers Media S.A.
2023-10-01
|
| סדרה: | Frontiers in Neurology |
| נושאים: | |
| גישה מקוונת: | https://www.frontiersin.org/articles/10.3389/fneur.2023.1275533/full |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|